CYP19A1 and neoplasm: The aim of the current study is to compare tumour size estimated by CE and MRI with the tumour size in surgical specimen, in order to determine which is the most accurate assessment to evaluate tumour response in patients with LABC treated neoadjuvant with aromatase inhibitor (NAAI) therapy.